Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 9/20 | 0.65 |
| ▸ | CA1 | P00915 | 7/20 | 0.65 |
| ▸ | CA9 | Q16790 | 5/20 | 0.65 |
| ▸ | CA12 | O43570 | 3/20 | 0.65 |
| ▸ | MMP1 | P03956 | 1/20 | 0.61 |
| ▸ | MMP2 | P08253 | 1/20 | 0.61 |
| ▸ | MMP9 | P14780 | 1/20 | 0.61 |
| ▸ | MMP8 | P22894 | 1/20 | 0.61 |
| ▸ | MMP13 | P45452 | 1/20 | 0.61 |
| ▸ | CA4 | P22748 | 2/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.53 |
| ▸ | KIF11 | P52732 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29705239 | 1.00 | CA2 (0.65) | CA2CA1CA9CA12MMP1 | |
| SCHEMBL8043466 | 0.98 | CA2 (0.63) | CA2CA1CA9CA12MMP1 | |
| Potassium SCHEMBL8043470 | 0.98 | CA2 (0.63) | CA2CA1CA9CA12MMP1 | |
| SCHEMBL27811943 | 0.98 | CA2 (0.63) | CA2CA1CA9CA12MMP1 | |
| Hydrochloric Acid SCHEMBL29969413 | 0.98 | CA2 (0.63) | CA2CA1CA9CA12MMP1 | |
| Trifluoroacetic Acid SCHEMBL29695834 | 0.90 | CA1 (0.63) | CA2CA1CA9CA12MMP1 | |
| Benzoic Acid SCHEMBL22653517 | 0.86 | SRD5A2 (0.61) | CA2CA1CA9CA12MMP1 | |
| SCHEMBL8863056 | 0.83 | CA1 (0.65) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL30859041 | 0.83 | CA1 (0.65) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL12841398 | 0.82 | CA2 (0.59) | CA2CA1CA9CA12CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 294 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473305-B2 | Pyrazole boronic acid compound, pharmaceutical composition containing same, and uses thereof | BEIJING SONGRUN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2025-11-18 | — | — | US | claimed |
| EP-4543870-A1 | NEW HETEROCYCLIC-CARBONYL-CYCLIC COMPOUNDS AS MAGL INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2025-04-30 | — | — | EP | claimed |
| CN-119301113-A | Novel heterocyclic carbonyl cyclic compounds as MAGL inhibitors | 豪夫迈·罗氏有限公司 | 2025-01-10 | — | — | CN | claimed |
| CN-119219810-A | Ionic polymer and preparation method and application thereof | 佛山绿动氢能科技有限公司 | 2024-12-31 | — | — | CN | claimed |
| CN-118725252-A | Sulfonyl iminopolyurethane single-ion polymer electrolyte membrane, and preparation method and application thereof | 哈尔滨工业大学 | 2024-10-01 | — | — | CN | claimed |
| US-20240174603-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | RAPPTA THERAPEUTICS OY (FI) | 2024-05-30 | — | — | US | claimed |
| WO-2023247670-A1 | NEW HETEROCYCLIC-CARBONYL-CYCLIC COMPOUNDS AS MAGL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-12-28 | — | — | WO | claimed |
| US-20230322816-A1 | PYRAZOLE BORONIC ACID COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USES THEREOF | BEIJING SONGRUN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-10-12 | — | — | US | claimed |
| CN-111526877-B | Compounds and compositions for IRE1 inhibition | 奥普提卡拉公司 | 2023-08-25 | — | — | CN | claimed |
| CN-114075227-B | Pyrazole boric acid compound, pharmaceutical composition containing pyrazole boric acid compound and application of pyrazole boric acid compound and pharmaceutical composition | 北京嵩润医药科技有限责任公司 | 2023-07-04 | — | — | CN | claimed |
| US-20030083331-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-05-01 | — | — | US | claimed |
| US-20030032644-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2003-02-13 | — | — | US | claimed |
| US-20020165232-A1 | Substituted N, N-disubstituted cycloalkyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | SIKORSKI JAMES A (US) | 2002-11-07 | — | — | US | claimed |
| US-20020165231-A1 | Substituted N-heteroaryl-N-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | SIKORSKI JAMES A (US) | 2002-11-07 | — | — | US | claimed |
| US-20020065271-A1 | Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion | PEYMAN ANUSCHIRWAN (DE) | 2002-05-30 | — | — | US | claimed |
| US-6313119-B1 | VITRONECTIN RECEPTOR ANTAGONISTS | ADVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-11-06 | — | — | US | claimed |
| EP-1115693-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL $i(TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | Monsanto Company (US) | 2001-07-18 | — | — | EP | claimed |
| EP-1049677-A1 | NOVEL SULFONAMIDE DERIVATIVES AS INHIBITORS OF BONE RESORPTION AND AS INHIBITORS OF CELL ADHESION | Aventis Pharma Deutschland GmbH (DE) | 2000-11-08 | — | — | EP | claimed |
| WO-2000018721-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
| WO-1999037621-A1 | NOVEL SULFONAMIDE DERIVATIVES AS INHIBITORS OF BONE RESORPTION AND AS INHIBITORS OF CELL ADHESION | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 1999-07-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12473305-B2 | Pyrazole boronic acid compound, pharmaceutical composition containing same, and uses thereof | PSMB11, PSMB7, PSMC5 | CA2 2758/4885CA1 2442/4885CA9 1525/4885 |
| US-20020165231-A1 | Substituted N-heteroaryl-N-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | CETP, LCAT, MTTP | CA2 4562/4885CA1 4825/4885CA9 4594/4885 |
| US-20020065271-A1 | Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion | SOST, SELPLG, BST2 | CA2 667/4885CA1 957/4885CA9 1482/4885 |
| US-20240174603-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | PPM1A, PPP2CA, PPP3CA | CA2 2400/4885CA1 1360/4885CA9 4321/4885 |
| US-20030083331-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | CA2 4443/4885CA1 4821/4885CA9 4463/4885 |
| US-20230322816-A1 | PYRAZOLE BORONIC ACID COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USES THEREOF | PSMB11, PSMB7, PSMC5 | CA2 2758/4885CA1 2442/4885CA9 1525/4885 |
| US-20030032644-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, PCTP | CA2 3853/4885CA1 4538/4885CA9 4009/4885 |
| US-20020165232-A1 | Substituted N, N-disubstituted cycloalkyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | CETP, DBI, PLTP | CA2 4517/4885CA1 4774/4885CA9 4570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.